Viewpoint Molecular Targeting of Coralville was awarded the Iowa Biotechnology Association's top award at this year's Partnering For Growth Biotech Innovation Showcase, held March 30-31 in Ankeny.             


Viewpoint Molecular Targeting is a startup that develops therapies and diagnostics for cancer, with a focus on metastatic melanoma. The lead product, VMT-MCR1, is a combination diagnostic-therapeutic radiopharmaceutical, a technology platform referred to as a "theranostic". The product can be used to precisely determine the location and extent of tumors in the body, and then be used to direct a precise dose of radiation to cancer cells.

IowaBio Executive Director Joe Hrdlicka said the event is intended to gather innovators, inventors and investors to collaborate on work specific to the field of biotechnology. The showcase provides a forum for biotech leaders in Iowa and beyond to present their innovations to potential investors. Viewpoint Molecular Targeting was presented with a $5,000 check in a presentation following the event.

"Our expert panel felt Viewpoint made the most compelling case for best company," Mr. Hrdlicka said in a press release. "We had 12 companies from around the country. Viewpoint's work exemplifies Iowa's leadership position in bioscience."